APTX Aptinyx Inc.

3.11
0  0%
Previous Close 3.11
Open
Price To Book 0.78
Market Cap 104,378,476
Shares 33,562,211
Volume 19,400
Short Ratio
Av. Daily Volume 249,842

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 2H 2019.
NYX-458
Parkinson’s Disease Cognitive Impairment (healthy volunteers)
Phase 2 data released June 10, 2019 - primary endpoint met.
NYX-2925
Fibromyalgia
Phase 2 data released January 16, 2019 - primary endpoint not met. Additional Phase 2 trial to be initiated 2H 2019.
NYX-2925
Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
Phase 2 trial initiation announced February 19, 2019 with data due 1H 2020.
NYX-783
Post-traumatic stress disorder (PTSD)

Latest News

  1. Aptinyx to Present at the 2019 BMO Prescription for Success Healthcare Conference
  2. Aptinyx Reports Positive Top-line Data from Phase 2 Study of NYX-2925 in Patients with Fibromyalgia, Demonstrating Significant Effects on Both Biomarkers and Patient-Reported Pain
  3. Could The Aptinyx Inc. (NASDAQ:APTX) Ownership Structure Tell Us Something Useful?
  4. Aptinyx Reports First Quarter 2019 Financial Results and Provides Corporate Update
  5. Were Hedge Funds Right About Dumping Aptinyx Inc. (APTX) ?
  6. Aptinyx Appoints Henry Gosebruch to Its Board of Directors
  7. Aptinyx to Report First Quarter 2019 Financial Results on Tuesday, May 14, 2019
  8. Biotech Bets and a Goodbye from a Favorite Expert
  9. Aptinyx Reports Positive Data from Phase 1 Study of Novel NMDA Receptor Modulator, NYX-458, in Healthy Volunteers
  10. Robust Analgesic Activity of Aptinyx’s NYX-2925 in Advanced DPN Patients Revealed Through Further Analysis of Data from Phase 2 Study
  11. Aptinyx to Present at 18th Annual Needham Healthcare Conference
  12. Data in Parkinson’s Disease Model in Non-human Primates Demonstrate Reversal of Cognitive Deficits with Novel NMDA Receptor Modulator, NYX-458
  13. Aptinyx to Present Detailed Results from Phase 2 Painful DPN Study of NYX-2925 at American Pain Society Scientific Meeting
  14. All You Need to Know About Aptinyx Inc. (APTX) Rating Upgrade to Buy
  15. Aptinyx to Present Preclinical Data on NYX-458 at the AD/PD 14th International Conference on Alzheimer’s & Parkinson’s Diseases
  16. Aptinyx Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline and Business Progress
  17. Aptinyx to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, March 21, 2019
  18. Aptinyx to Present at Cowen and Company 39th Annual Health Care Conference
  19. Aptinyx to Present at 8th Annual SVB Leerink Global Healthcare Conference
  20. Aptinyx Initiates Phase 2 Study to Evaluate Safety and Efficacy of NYX-783 in Patients with Post-Traumatic Stress Disorder